Vermillion CEO Gail Page to step down
This article was originally published in Clinica
Diagnostics specialist Vermillion has started looking for a successor to president and CEO Gail Page after announcing that she will leave the company. The firm, which is seeking new leadership for its commercial phase of development, hopes to find a replacement by September. Ms Page has led Vermillion since 2004; during this time, the firm has seen its OVA1 ovarian cancer blood test approved by the US FDA (www.clinica.co.uk, 16 September 2009) and launched by partner Quest Diagnostics (www.clinica.co.uk, 10 March 2010). She was also "fundamental" in developing the relationship with Quest, and helped Vermillion raise over $110m in funding. Ms Page has resigned from the board of directors, but will continue to head up the company until her successor is found.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.